- Home
- CPZ vs TLSI Comparison
CPZ vs TLSI Comparison
Compare CPZ & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- TLSI
- Stock Information
- Founded
- CPZ 2019
- TLSI 2010
- Country
- CPZ United States
- TLSI United States
- Employees
- CPZ N/A
- TLSI N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- CPZ Finance
- TLSI Health Care
- Exchange
- CPZ Nasdaq
- TLSI Nasdaq
- Market Cap
- CPZ 298.2M
- TLSI 244.3M
- IPO Year
- CPZ N/A
- TLSI N/A
- Fundamental
- Price
- CPZ $15.03
- TLSI $4.61
- Analyst Decision
- CPZ
- TLSI Strong Buy
- Analyst Count
- CPZ 0
- TLSI 3
- Target Price
- CPZ N/A
- TLSI $10.67
- AVG Volume (30 Days)
- CPZ 63.0K
- TLSI 92.2K
- Earning Date
- CPZ 01-01-0001
- TLSI 11-13-2025
- Dividend Yield
- CPZ 11.07%
- TLSI N/A
- EPS Growth
- CPZ N/A
- TLSI N/A
- EPS
- CPZ N/A
- TLSI N/A
- Revenue
- CPZ N/A
- TLSI $40,207,000.00
- Revenue This Year
- CPZ N/A
- TLSI $57.25
- Revenue Next Year
- CPZ N/A
- TLSI $54.05
- P/E Ratio
- CPZ N/A
- TLSI N/A
- Revenue Growth
- CPZ N/A
- TLSI 49.52
- 52 Week Low
- CPZ $13.17
- TLSI $3.42
- 52 Week High
- CPZ $16.11
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- CPZ 29.00
- TLSI 49.69
- Support Level
- CPZ $15.06
- TLSI $3.79
- Resistance Level
- CPZ $15.34
- TLSI $4.88
- Average True Range (ATR)
- CPZ 0.24
- TLSI 0.33
- MACD
- CPZ 0.02
- TLSI 0.01
- Stochastic Oscillator
- CPZ 31.56
- TLSI 73.85
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.